TENX

Tenax Therapeutics

Fundamental data last updated:March 30, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/13/26

Business Summary

Tenax Therapeutics is a biotechnology company focused on developing therapeutic products for patients with cardiovascular and pulmonary diseases. The company conducts research and clinical development aimed at advancing treatments for conditions with significant unmet medical needs.

 


Analyze TENX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$256

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

2.6

EV / EBITDA

-4.7

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.34

Next Year EPS Growth Estimate

-$1.46

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-54.20%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

2

Altman Z-Score

15.9

Return on Invested Capital (ROIC)

-59.70%

Current Ratio

14.6

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze TENX on TradingView

Gainseekers Quantitative Analysis

Summary

Tenax Therapeutics is a small-cap biotechnology company with a market capitalization of $256 million, operating with negative earnings of -4.7 EPS and an operating margin of -54.20%. The company does not currently generate positive earnings, and profitability metrics such as P/E and return on equity are not available. With a price-to-book ratio of 2.6 and institutional ownership at 28.67%, the stock reflects measured external participation amid ongoing financial losses.

AI Exposure / Tech Reliance

As a biotechnology company, Tenax Therapeutics’ operations are primarily focused on drug development rather than artificial intelligence, indicating limited direct AI exposure. Its technology reliance is centered more on clinical research and pharmaceutical innovation than on AI-driven platforms.

The Bull Case

The company’s EPS is projected to improve to -$1.34 next year, suggesting a narrowing of losses. With a consensus rating of 0.90% and a mean target price of 1.25, there may be expectations for stabilization or upside if development milestones are met.

The Bear Case

The company currently reports negative EPS of -4.7 and a deeply negative operating margin of -54.20%, highlighting ongoing financial strain. Additionally, sales growth next year is projected at -$1.46, reinforcing concerns about continued revenue and profitability challenges.

Market Sentiment & Smart Money

Short Interest %

0.90%

Analyst Consensus

1.25

Average Analyst Price Target

$28.67

Institutional Ownership %

46.30%

1-Year Beta

0.29

Insider Buying % (6 Mo)

0.10%%

Distance to 52-Week High

81.10%

Distance to 52-Week Low

321.80%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.